PDCD1 and cancer: Thus, this study attempted to employ the ASCO-VF and the ESMO-MCBS to describe the clinical benefit of all approved PD-1/PD-L1 inhibitors for treating malignant tumors, and calculated the unit time cost of each agent, so as to explore a correlation between clinical benefit and price of drugs, likewise the correlation analyses in the subgroups of different agents or indications.